Notice: Undefined property: stdClass::$name in /home/ on line 140

Notice: register_post_type was called incorrectly. Post type names must be between 1 and 20 characters in length. Please see Debugging in WordPress for more information. (This message was added in version 4.2.0.) in /home/ on line 5313

Notice: Constant WP_MEMORY_LIMIT already defined in /home/ on line 126
BioNTech and Valneva stock: With the best recommendations! - Financial Trends

BioNTech and Valneva stock: With the best recommendations!

Dear Reader,

The stock market week is not over yet, but until Friday morning it can truly not be called successful for BioNTech and Valneva. In early trading in Frankfurt on Friday, the Valneva stock improved by a good one percent to 9.59 euros, while BioNTech gained 0.7 percent to 149.00 euros. With this, however, the papers of the vaccine companies still show a slight weekly minus. This is somewhat surprising, as both BioNTech and Valneva had positive news to report from their vaccine programs against COVID-19 during the week.

WHO recommends Valneva’s vaccine

Valneva’s Corona vaccine, in particular, has now cleared a not insignificant hurdle: The French-Austrian company confirmed “that the World Health Organization (WHO) has issued recommendations for the use of the company’s inactivated COVID-19 vaccine.”

According to the statement, the WHO’s preliminary recommendations for the use of Valneva’s VLA2001 vaccine were developed based on the recommendations of the Strategic Expert Group on Immunization (SAGE) at its extraordinary meeting on August 11, 2022 “and published in its background document.”

Valneva vaccine also suitable as a booster

The WHO’s preliminary recommendations also include a recommendation for a booster dose of VLA2001 four to six months after completion of the first vaccination series, according to Valneva, “and indicate that a booster dose of VLA2001 may be considered after the first vaccination with ChAdOx1-S (AstraZeneca),” according to the statement. WHO may further update its preliminary recommendations to include additional uses of Valneva’s COVID-19 vaccine as new data become available, it said.

“We are pleased that WHO has issued recommendations for the use of Valneva’s inactivated COVID-19 vaccine, and believe these guidelines can assist others in assessing the potential of our vaccine to contribute to public health,” commented Juan Carlos Jaramillo, MD, chief medical officer of Valneva. “We look forward to working with the WHO to review VLA2001 for prequalification and continuing our discussions with governments considering the vaccine for their portfolios.”

BioNTech coming soon with Omikron vaccine

BioNTech also had good news to report. According to media reports, BioNTech expects approval of its Corona variant vaccine as early as next week, followed by rapid delivery. “We can ship very promptly, hopefully starting in early September,” said Ugur Sahin, CEO and co-founder of BioNTech, in a pre-published interview with the news magazine Spiegel.

First, he expects approval of the vaccine based on the original Omikron subtype BA.1, according to WirtschaftsWoche. However, according to the report, there is also a booster for the now dominant BA.5 subtype, which is expected to be approved only a little later. BioNTech is currently submitting the final documents to the EMA. “Then it can go quickly here, too,” Sahin is quoted as saying.

Update on efficacy in infants

Also significant: Together with partner Pfizer, the Mainz-based company on Tuesday announced a data update on the efficacy analysis of Pfizer-BioNTech’s COVID-19 vaccine from a Phase 2/3 trial in children aged 6 months to 4 years. The study had evaluated the vaccine in a vaccination series consisting of three 3-µg doses. The results confirm previously published interim vaccine efficacy data collected in March and April 2022, according to BioNTech.

“These results confirm that three 3-µg doses of our COVID-19 vaccine provide infants with a high level of protection while maintaining a favorable safety profile – this during a period when Omikron variant BA.2 was the predominant variant” said Ugur Sahin. In parallel, BioNTech is developing a bivalent vaccine adapted to Omikron variants BA.4/BA.5 in this age group to address these variants, he added. According to the study, vaccine efficacy for prevention in children aged 6 to 23 months was 75.8%.

High price targets for BioNTech stock

Whether the Valneva stock will ever reach its high of 30.50 euros again seems questionable. It is too uncertain whether the French-Austrian company will ever be able to make a serious profit from VLA2001, as the vaccine only received its approval in the EU in June. The situation is quite different at BioNTech, whose vaccine has already been administered billions of times over – and brought the Main-based company profits of more than ten billion euros in 2021 alone. The analysts’ assessments are therefore correspondingly positive – in some cases with high price targets.

  • Goldman Sachs: $200.00, +34.63%
  • Deutsche Bank: 180.00$, +21.16%
  • UBS AG: 168.00$ +13.09%
  • JP Morgan: 183.00$ +23.18%

Berenberg Bank stood out in early August: the biotech company is on track to reach its sales target for Covid-19 products, analyst Zhiqiang Shu wrote after the quarterly results. However, sales in the second quarter fell short of expectations, he added. Order books should fill up again, however, should booster vaccines receive approval. With a lowered price target for BioNTech stock from $350 to $312, the Berenberg expert still expects the stock to more than double.